Cox-2 inhibitors: still no decisive action.
(1) Evidence that the Cox-2 inhibitors have severe cardiovascular adverse effects continues to accumulate, including an increase in overall mortality in several trials of rofecoxib. (2) Yet regulatory agencies on both sides of the Atlantic have so far only taken half-measures, issuing new contraindications and warnings that complicate matters for prescribers (but not for the companies concerned), and leave patients exposed to significant dangers.